ClinicalTrials.gg
CompletedNCT04805411Updated Apr 15, 2022

Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

A Phase 2 interventional study of CM310 and Placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Completed at 25 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-04-15.

Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.

Enrollment
9th of 12
120 · median 170
Started
2021
with 1 other
Phase 2
5 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
12 of 12
Keymed Biosciences Co.Ltd

Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 9th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About stapokibart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing stapokibart in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled phase IIb study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in moderate-severe AD subjects. The study consists of 3 periods, a up-to-4-week Screening Period, a 16-week randomized Treatment Period and a 8-week Safety Follow-up Period.

Read the detailed description

Subjects will be required to apply moisturizers after ICF signed and continue throughout the study.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

Keywords

  • Atopic dermatitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed as AD for at least 12 months before Screening, with below requirements: 1)EASI score ≥16 at Screening and Baseline; 2) IGA score ≥3 (0-5 points scale) at Screening and Baseline; 3) ≥10% BSA of AD involvement at Screening and Baseline; 4) Pruritus NRS average score ≥3 at Baseline.
  • Inadequate response to topical medications.

Exclusion criteria

Exclusion Criteria:

  • Not enough washing-out period for previous therapy.
  • Concurrent disease/status which may potentially affect the efficacy/safety judgement.
  • Organ dysfunction.
  • pregnancy.
  • Other.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    High-dose arm

    600mg for 1st dose, and then 300 mg for 2-8nd doses, every 2 weeks, SC

    Biological: CM310

  • Experimental
    low-dose arm

    300mg for 1st dose, and then 150 mg for 2-8nd doses, every 2 weeks, SC

    Biological: CM310

  • Placebo comparator
    placebo

    placebo for 1-8 doses, every 2 weeks, SC

    Biological: Placebo

Interventions

  • BiologicalCM310

    IL-4Rα monoclonal antibody

  • BiologicalPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. EASI-75

    Proportion of subjects with EASI-75 (≥75 percent improvement from baseline)

    Time frame: at Week 16

Secondary outcomes

  1. Investigator's Global Assessment (IGA) 0/1

    Proportion of subjects with IGA 0 or 1 (on a 6-point scale, range from 0-5 point, higher scores mean a worse disease severity) and a reduction from baseline of ≥2 points.

    Time frame: at week 16

  2. reduction of IGA from baseline of ≥ 2 points

    Proportion of subjects with IGA 0 or 1 (on a 6-point scale, range from 0-5 point, higher scores mean a worse disease severity) and a reduction from baseline of ≥2 points.

    Time frame: at week 16

  3. The Eczema Area and Severity Index (EASI)-90

    Proportion of subjects with EASI-90 (≥90 percent improvement from baseline)

    Time frame: at week 16

  4. The Eczema Area and Severity Index (EASI)-50

    Proportion of subjects with EASI-50 (≥50 percent improvement from baseline)

    Time frame: at week 16

  5. Improvement of Numerical Rating Scale (NRS)

    Proportion of subjects with improvement (reduction) of pruritus NRS of ≥4 points from baseline. The range of NRS is from 0 (no itch)-10 (worst imaginable itch).

    Time frame: at week 16

  6. Body Surface Area (BSA)

    Change from baseline in percent of BSA

    Time frame: Baseline to Week 24

  7. Dermatology Life Quality Index (DLQI)

    Change from baseline in DLQI

    Time frame: Baseline to Week 24

  8. Safety parameters

    Incidence of AE, abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Time frame: Baseline to Week 24

  9. Pharmacokinetics parameters

    trough concentration and exposure of CM310

    Time frame: Baseline to Week 24

  10. Pharmacodynamics

    Serum Thymus and activation regulated chemokine (TARC)

    Time frame: Baseline to Week 24

  11. Pharmacodynamics

    Total IgE level

    Time frame: Baseline to Week 24

  12. immunogenicity

    Detection of anti-drug antibody (ADA)

    Time frame: Baseline to Week 24

07

Study locations

25 sites
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing, China
  • Beijing Friendship Hospital,Capital Medical University
    Beijing, Beijing, China
  • Peking University People's Hospital
    Beijing, Beijing, China
  • Peking University Third Hospital
    Beijing, Beijing, China
  • Chongqing Traditional Chinese Hospital
    Chongqing, Chongqing, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Wuxi Second Hospital
    Wuxi, Jiangsu, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu, China
  • First Hospital of Jilin University
    Changchun, Jilin, China
  • Second Hospital of Jilin University
    Changchun, Jilin, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • Shandong Provincial Hospital of Dermatology
    Jinan, Shandong, China
  • Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai, China
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang, China
  • Ningbo Second Hospital
    Ningbo, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Nov 2021, 8 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 8 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2021
First posted
Mar 18, 2021
StartActual
Feb 24, 2021
Primary completionActual
Nov 8, 2021
CompletionActual
Nov 8, 2021
Last update
Apr 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04805411
Responsible party
Sponsor
First posted
Mar 18, 2021
Start date
Feb 24, 2021
Primary completion
Nov 8, 2021
Completion
Nov 8, 2021
Last update
Apr 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion